Friday, May 15

08:15–08:30 Welcome

SESSION I – Molecular pathogenesis of MPNs
Chair(s): Robert Kralovics

08:30–08:50 Keynote lecture: Immortal hematopoietic stem cells and their epigenetic regulation
Peggy Goodell (Houston)

08:50–08:55 Discussion

08:55–09:10 Lessons about MPN pathogenesis from germline and somatic studies
Radek Skoda (Basel)

09:10–09:15 Discussion

09:15–09:30 MPN stem/cell directed therapeutics
Ronald Hoffman (New York)

09:30–09:35 Discussion

09:35–09:50 Molecular pathogenesis of PV/ET
Tony R. Green (Cambridge)

09:50–09:55 Discussion

09:55–10:05 Short talk

10:05–10:10 Discussion

10:10–10:30 Panel discussion or controversial debates

10:30–10:55 Coffee Break

SESSION II – Novel MPN therapeutics
Chair(s): Radek Skoda

10:55–11:10 Targeting the MAPK pathway
Sara Meyer (Basel)

11:10–11:15 Discussion

11:15–11:30 Role of the JH2 pseudokinase in MPN biology and therapy
Olli Silvennoinen (Helsinki)

11:30–11:35 Discussion

11:35–11:50 Structure based insights into MPN therapeutics
Stefan N. Constantinescu (Brussels)

11:50–11:55 Discussion

11:55–12:10 Novel approaches to targeting CALR-mutant MPN
Robert Kralovics (Vienna)

12:10–12:15 Discussion

12:15–12:25 Short talk

12:25–12:30 Discussion
12:30-12:50  Panel discussion or controversial debates

12:50-14:35  Lunch

13:20-14:20  Satellite symposium (slot already booked)

SESSION III – MPN Initiation and clonal evolution
Chair(s): Tony R. Green

14:35-14:50  Single cell approaches to deciphering MPN biology  Stephen Oh (St Louis)
14:50-14:55  Discussion

14:55-15:10  Single cell studies to uncover novel insights into MPN pathogenesis  Adam Mead (Oxford)
15:10-15:15  Discussion

15:15-15:30  Role of inflammation in MPN initiation and progression  Angela Fleischman (Irvine)
15:30-15:35  Discussion

15:35-15:50  Non-genetic mechanisms of clonal expansion  David Kent (York)
15:50-15:55  Discussion

15:55-16:05  Short talk
16:05-16:10  Discussion

16:10-16:30  Panel discussion or controversial debates

16:30-17:00  Coffee break

SESSION IV – Murine MPN models and pathogenesis/therapeutic studies
Chair(s): Ann Mullally

17:00-17:15  Targeting the microenvironment as a therapeutic approach in MPN  Simón Méndez-Ferrer (Cambridge)
17:15-17:20  Discussion

17:20-17:35  LSD1 inhibition as a therapeutic approach in MPN  Heike L. Pahl (Freiburg)
17:35-17:40  Discussion

17:40-17:55  JAK2 mutation in endothelial cells: myth or reality?  Bruno Cassinat (Paris)
17:55-18:00  Discussion

18:00-18:15  Pathogenesis and therapy of MPN-associated thrombosis  Chloé James (Bordeaux)
18:15-18:20  Discussion

18:20-18:35  Modeling progression to myelofibrosis  Jean-Luc Villeval (Paris)
18:35-18:40  Discussion

18:40-18:50  Short talk
18:50-18:55  Discussion

18:55-19:15  Panel discussion or controversial debates

19:15  Get together and poster walks (stand up cocktails and buffet dinner for all)
09:00-10:00 Satellite symposium (slot already booked)

09:00-10:00 Simultaneous Meet the Expert sessions (non-clinical):
1. Role of inflammation in MPN
   Angela Fleischman (Irvine)
2. Cellular and molecular regulators of HSCs in myeloid malignancies
   David Kent (York)
3. HSC niches in MPN
   Simón Méndez-Ferrer (Cambridge)

SESSION V – Molecular pathogenesis and therapy of MPN progression and leukaemic transformation
Chair(s): Raajit K. Rampal

10:10-10:25 Unusual firms of eosinophilias
   (FGFR1 inhibitors, MoAb for other eosinophilias)
   Andreas Reiter (Mannheim)
10:25-10:30 Discussion
10:30-10:45 Genetic studies of MPN leukaemic transformation
   Vikas Gupta (Toronto)
10:45-10:50 Discussion

10:50-11:20 Coffee break

11:20-11:35 Therapeutic approaches in post-MPN AML
   John O. Mascarenhas (New York)
11:35-11:40 Discussion
11:40-11:55 Transplantation as a therapeutic in post-MPN AML
   Nicolaus Kröger (Hamburg)
11:55-12:00 Discussion

12:00-12:10 Short talk
12:10-12:15 Discussion
12:15-12:25 Short talk
12:25-12:30 Discussion
12:30-12:50 Panel discussion or controversial debates

12:50-14:30 Lunch

13:20-14:20 Satellite symposium (slot already booked)

SESSION VI – Recent advances in therapeutics (1)
Chair(s): Jean-Jacques Kiladjian

14:30-14:50 Keynote lecture: Combination therapies for myelofibrosis
   Ruben Mesa (San Antonio)
14:50-14:55 Discussion

14:55-15:10 Prognostic scores in MPN
   Alessandro M. Vannucchi (Florence)
15:10-15:15 Discussion

15:15-15:30 Interferon versus hydroxyurea: lessons from randomized studies
   Jean-Jacques Kiladjian (Paris)
15:30-15:35 Discussion
15:35-15:50  Molecular pathogenesis of progression from MPN to AML  Raajit K. Rampal (New York)
15:50-15:55  Discussion

15:55-16:15  Panel discussion or short communications or controversial debates

**16:15-16:45  Coffee break**

**SESSION VII – Recent advances in therapeutics (2)**
**Chair(s): Alessandro M. Vannucchi**

16:45-17:00  Insights in diagnosis and management of CMML  Eric Solary (Paris)
17:00-17:05  Discussion

17:05-17:20  ET Therapy  Tiziano Barbui (Bergamo)
17:20-17:25  Discussion

17:25-17:40  Therapy of overlap MPN/MDS syndromes  Lionel Ades (Paris)
17:40-17:45  Discussion

17:45-18:00  Role of aspirin in ET  Stéphane Giraudier (Paris)
18:00-18:05  Discussion

18:05-18:25  Panel discussion or controversial debates

**Free evening**

---

**Sunday, May 17**

07:30-8:30  **3 Simultaneous Breakfast Meet the Expert Sessions (Clinical):**
1. Title TBA  Raajit K. Rampal (New York)
2. How to recognize and manage ruxolitinib treatment failure?  John O. Mascarenhas (New York)
3. MPN diagnosis: The place of Red cell Mass measurement in the molecular Era  Stéphane Giraudier (Paris)

**SESSION VIII – Molecular pathogenesis of MPN**
**Chair(s): Angela Fleischman**

08:40-08:55  CALR mutations in the development of MPN using mouse modeling  Caroline Marty (Villejuif)
08:55-09:00  Discussion

09:00-09:15  Initiation and progression of CALR mutant MPN  Ann Mullally (Boston)
09:15-09:20  Discussion

09:20-09:35  Deciphering the role of clonal evolution in MPN pathogenesis and progression  Ross L. Levine (New York)
09:35-09:40  Discussion

09:40-09:50  Short talk
09:50-09:55  Discussion

09:55-10:05  Short talk
10:05-10:10  Discussion
10:10-10:30  Panel discussion or controversial debates

10:30-11:00  Coffee break

SESSION IX – Novel MPN therapeutics
Chair(s): Stefan N. Constantinescu

11:00-11:15  Targeting splicing factors  Timothy Graubert (Boston)
11:15-11:20  Discussion

11:20-11:35  Targeting aberrant self-renewal in MPN  Catriona Jamieson (La Jolla)
11:35-11:40  Discussion

11:40-11:55  Novel approaches to mastocytosis therapy  Jason Gotlib (Stanford)
11:55-12:00  Discussion

12:00-12:15  Novel JAK inhibitors for myelofibrosis  Prithviraj Bose (Houston)
12:15-12:20  Discussion

12:20-12:40  Panel discussion or controversial debates

12:40-12:55  Closing Remarks

MEETING CLOSURE